ProMedEx net profit down 8% to SAR 19 mln in 2022

12/06/2023 Argaam Exclusive

View other reports

Net profit of Professional Medical Expertise Co. (ProMedEx), which is slated to list on Nomu-Parallel Market, slumped 8% to SAR 19 million by the end of 2022, from SAR 20.6 million a year earlier.



Financials (M)

Item 2021 2022 Change‬
Revenues 131.26 176.05 34.1 %
Gross Income 66.91 83.65 25.0 %
Operating Income 24.45 26.01 6.4 %
Net Income 20.62 19.02 (7.8 %)
Average Shares 0.77 3.50 -
EPS (Riyals) 26.74 5.43 (79.7 %)


Current Quarter Comparison (M)

Compared With The
Item Q4 2021 Q4 2022 Change‬
Revenues 50.13 58.45 16.6 %
Gross Income 25.09 30.57 21.8 %
Operating Income 11.91 13.79 15.8 %
Net Income 11.43 11.87 3.9 %
Average Shares 0.77 3.50 -
EPS (Riyals) 14.82 3.39 (77.1 %)

This came as the company’s gross profit margin slumped to 48% in 2022, from 51% in the year before. This was in addition to the decrease in operating profit margin to 15% last year, compared to 19% in 2021, amid higher administrative and marketing expenses.

 

Moreover, ProMedEx reported an expected credit loss provision of SAR 2.4 million in 2022, compared to SAR 441,000 a year ago.

 

Further, financing costs (FCs) increased to SAR 4.7 million during the same year, versus SAR 2.7 million in 2021.

 

This was offset by an uptick in revenue from SAR 131.3 million in 2021 to SAR 176.1 million in the year after.

 

Total shareholders’ equity, no minority interest, stood at SAR 73.19 million in 2022, compared to SAR 39.76 million in 2021.

 

ProMedEx’s cash balance, as of Dec. 31, 2022, amounted to SAR 5.3 million. In detail, cash from operating activities came in at SAR 3.9 million by the end of the year, while capital expenditure and net cash from financing activities were at SAR 6.4 million and SAR 2.2 million, respectively.

 

The company’s public sector sales amounted to SAR 120.6 million by the end of 2022, compared to SAR 86.9 million in 2021.

 

Private business sales stood at SAR 55.4 million last year, against SAR 44.4 million in 2021.

 

Geographically, the Kingdom’s sales amounted to SAR 164.3 million in 2022, compared to SAR 126.8 million in 2021.

 

Elsewhere, the UAE sales reached SAR 11.8 million by the end of 2022, compared to SAR 4.5 million in the year before.

 

Shareholders approved, during the extraordinary general meeting held on June 19, 2022, increasing the company’s capital to SAR 35 million by transferring SAR 27.3 million from related parties and SAR 7.2 million from retained earnings.



Financial results (Million)

Period Revenues Change Gross Income Change Net Income Change EPS(Riyal)
Q1 2013 - - - - - - -
Q2 2013 - - - - - - -
Q3 2013 - - - - - - -
Q4 2013 - - - - - - -
Q1 2014 - - - - - - -
Q2 2014 - - - - - - -
Q3 2014 - - - - - - -
Q4 2014 - - - - - - -
Q1 2015 - - - - - - -
Q2 2015 - - - - - - -
Q3 2015 - - - - - - -
Q4 2015 - - - - - - -
Q1 2016 - - - - - - -
Q2 2016 - - - - - - -
Q3 2016 - - - - - - -
Q4 2016 - - - - - - -
Q1 2017 - - - - - - -
Q2 2017 - - - - - - -
Q3 2017 - - - - - - -
Q4 2017 - - - - - - -
Q1 2018 - - - - - - -
Q2 2018 - - - - - - -
Q3 2018 - - - - - - -
Q4 2018 - - - - - - -
Q1 2019 - - - - - - -
Q2 2019 - - - - - - -
Q3 2019 - - - - - - -
Q4 2019 - - - - - - -
Q1 2020 - - - - - - -
Q2 2020 - - - - - - -
Q3 2020 - - - - - - -
Q4 2020 - - - - - - -
Q1 2021 - - - - - - -
Q2 2021 - - - - - - -
Q3 2021 - - - - - - -
Q4 2021 50.13 - 25.09 - 11.43 - 14.82
Q1 2022 - - - - - - -
Q2 2022 - - - - - - -
Q3 2022 43.75 - 18.87 - 1.96 - 0.56
Q4 2022 58.45 16.6 % 30.57 21.8 % 11.87 3.9 % 3.39
2022 176.05 34.1 % 83.65 25.0 % 19.02 (7.8 %) 5.43

Profitability

Period Gross Margin OIBDA Margin Net Margin Before Unusual Items
Q1 2013 - - -
Q2 2013 - - -
Q3 2013 - - -
Q4 2013 - - -
Q1 2014 - - -
Q2 2014 - - -
Q3 2014 - - -
Q4 2014 - - -
Q1 2015 - - -
Q2 2015 - - -
Q3 2015 - - -
Q4 2015 - - -
Q1 2016 - - -
Q2 2016 - - -
Q3 2016 - - -
Q4 2016 - - -
Q1 2017 - - -
Q2 2017 - - -
Q3 2017 - - -
Q4 2017 - - -
Q1 2018 - - -
Q2 2018 - - -
Q3 2018 - - -
Q4 2018 - - -
Q1 2019 - - -
Q2 2019 - - -
Q3 2019 - - -
Q4 2019 - - -
Q1 2020 - - -
Q2 2020 - - -
Q3 2020 - - -
Q4 2020 - - -
Q1 2021 - - -
Q2 2021 - - -
Q3 2021 - - -
Q4 2021 50.06 % - 22.79 %
Q1 2022 - - -
Q2 2022 - - -
Q3 2022 46.83 % 17.29 % 14.26 %
Q4 2022 48.93 % 20.27 % 16.58 %
2022 47.51 % 16.52 % 10.80 %


Per Share Data (Riyal)

Compared With The
Period Shares Outstanding (M) EPS (Riyal) Adjusted EPS (Riyal) Book Value (BV)
Q1 2013 - - - -
Q2 2013 - - - -
Q3 2013 - - - -
Q4 2013 - - - -
Q1 2014 - - - -
Q2 2014 - - - -
Q3 2014 - - - -
Q4 2014 - - - -
Q1 2015 - - - -
Q2 2015 - - - -
Q3 2015 - - - -
Q4 2015 - - - -
Q1 2016 - - - -
Q2 2016 - - - -
Q3 2016 - - - -
Q4 2016 - - - -
Q1 2017 - - - -
Q2 2017 - - - -
Q3 2017 - - - -
Q4 2017 - - - -
Q1 2018 - - - -
Q2 2018 - - - -
Q3 2018 - - - -
Q4 2018 - - - -
Q1 2019 - - - -
Q2 2019 - - - -
Q3 2019 - - - -
Q4 2019 - - - -
Q1 2020 - - - -
Q2 2020 - - - -
Q3 2020 - - - -
Q4 2020 - - - -
Q1 2021 - - - -
Q2 2021 - - - -
Q3 2021 - - - -
Q4 2021 0.77 14.82 14.82 51.56
Q1 2022 - - - -
Q2 2022 - - - -
Q3 2022 3.50 3.83 3.83 17.50
Q4 2022 3.50 7.22 7.22 20.91

Multiple Ratios (End of Period Price)

Compared With The
Period P/E Adjusted P/E Price/book
Q1 2013 - - -
Q2 2013 - - -
Q3 2013 - - -
Q4 2013 - - -
Q1 2014 - - -
Q2 2014 - - -
Q3 2014 - - -
Q4 2014 - - -
Q1 2015 - - -
Q2 2015 - - -
Q3 2015 - - -
Q4 2015 - - -
Q1 2016 - - -
Q2 2016 - - -
Q3 2016 - - -
Q4 2016 - - -
Q1 2017 - - -
Q2 2017 - - -
Q3 2017 - - -
Q4 2017 - - -
Q1 2018 - - -
Q2 2018 - - -
Q3 2018 - - -
Q4 2018 - - -
Q1 2019 - - -
Q2 2019 - - -
Q3 2019 - - -
Q4 2019 - - -
Q1 2020 - - -
Q2 2020 - - -
Q3 2020 - - -
Q4 2020 - - -
Q1 2021 - - -
Q2 2021 - - -
Q3 2021 - - -
Q4 2021 - - -
Q1 2022 - - -
Q2 2022 - - -
Q3 2022 - - -
Q4 2022 - - -

Business Segments (Million)

Compared With The
Period Public sector sales Private sector sales
Q4 2021 38.01 12.11
Q4 2022 47.05 11.40

Current
Market Cap (M Riyal) 290.50
Enterprise Value (EV) (M) 349.20
Shares Outstanding ((M)) 3.50
Book Value (BV) ( Riyal) 27.77
Par Value ( Riyal) 10.00
Adjusted P/E (Last12) 11.69
Price/book 2.99

Share Price

Professional Medical Expertise Co. (PRO MEDEX)


Comments {{getCommentCount()}}

Be the first to comment

{{Comments.indexOf(comment)+1}}
{{comment.FollowersCount}}
{{comment.CommenterComments}}
loader Train
Sorry: the validity period has ended to comment on this news
Opinions expressed in the comments section do not reflect the views of Argaam. Abusive comments of any kind will be removed. Political or religious commentary will not be tolerated.